



CITURGIA BIOCHEMICALS LIMITED

Regd. Office: 6/C, Ostwal Park Building No. 4, Chsl, Near Jesal Park, Jain Temple,
Bhayandar East, Thane-401105, Maharashtra. CIN: L24100MH1974PLC017773

Website: www.citurgiabio.com; E-mail id: citurgia_bio@yahoo.com

Date: 28th February, 2023

To,

**BSE Limited
P J Towers, Dalal Street
Mumbai – 400001
Scrip Code: 506373,
Scrip ID: CITURGIA**

Sub: Submission of Revised Unaudited Financial Results for Quarter ended on 31st December, 2022.

Please find enclosed herewith Revised Unaudited Financial Results for the Quarter ended 31st December, 2022 as approved by the Board of directors in their meeting held on 14th February, 2023.

Further, we would like to inform you that in earlier submission dated 15th February, 2023, due to some clerical mistake Limited Review Report issued by the statutory auditor for the quarter ended on 31st December, 2022 could not be submitted.

However, except above change, there is no change in the results submitted to stock exchanges on 15th February, 2023.

We regret the inconvenience caused and request you to kindly take the above information on record and do the needful.

FOR CITURGIA BIOCHEMICALS LIMITED



**KASHI NATH
WHOLE TIME DIRECTOR
DIN No. 02072952**

Amount in Lakh							
STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST, DECEMBER 2022							
		Quarter Ended			Period Ended		Year Ended
Particulars		3 Months ended 31/12/2022	Preceding 3 months ended 30/09/2022	Corresponding 3 months ended 31/12/2021	Year to Figure for current year ended 31.12.2022	Year to Figure for previous year ended 31.12.2021	Current Ended 31/03/2022
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I.	Total Income from Operations	-	-	-	-	-	-
II.	Other Income	-	-	-	-	-	-
III.	Total Revenue (I+II)	-	-	-	-	-	-
IV.	Expenses						
	a) Cost of Materials consumed	-	-	-	-	-	-
	b) Purchase of Stock-in-trade	-	-	-	-	-	-
	c) Changes in inventories of finished goods, WIP and stock in trade	-	-	-	-	-	-
	d) Employee benefits expenses	4.40	4.40	4.40	11.80	10.80	15.91
	e) Depreciation and amortisation expenses	5.73	5.95	5.73	16.83	17.65	22.56
	f) Other expenses	0.13	-	0.52	0.38	22.31	1.94
	Total Expenses	10.26	10.35	10.65	29.01	50.76	40.41
V	Profit/(Loss) before exceptional and extraordinary items and tax (III-V)	(10.26)	(10.35)	(10.65)	(29.01)	(50.76)	(40.41)
VI	Exceptional Items	-	-	-	-	-	-
VII	Profit/(Loss) before extraordinary items and tax (VI-VII)	(10.26)	(10.35)	(10.65)	(29.01)	(50.76)	(40.41)
VIII	Extraordinary items	-	-	-	-	-	-
IX	Profit/(Loss) before tax (VIII-IX)	(10.26)	(10.35)	(10.65)	(29.01)	(50.76)	(40.41)
X	Tax expenses						
	a) Current Tax	-	-	-	-	-	-
	a) Income Tax Adjustment	-	-	-	-	-	-
	a) MAT Credit Entitlement	-	-	-	-	-	-
	b) Deferred Tax Liabilities / (Assets)	-	-	-	-	-	-
XI	Profit (Loss) for the period from continuing operations (IX-X)	(10.26)	(10.35)	(10.65)	(29.01)	(50.76)	(40.41)
XII	Profit/(loss) from discontinuing operations	-	-	-	-	-	-
XIII	Tax expense of discontinuing operations	-	-	-	-	-	-
XIV	Profit/(loss) from Discontinuing operations (after tax) (XII-XIII)	-	-	-	-	-	-
XV	Profit (Loss) for the period (XI + XIV)	(10.26)	(10.35)	(10.65)	(29.01)	(50.76)	(40.41)
XVI	Other Comprehensive Income						
	A (i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
XVI I	Total Comprehensive Income for the period (XV+XVI) (Comprising Profit (Loss) and Other Comprehensive Income for the period)	(10.26)	(10.35)	(10.65)	(29.01)	(50.76)	(40.41)
XVI II	Earnings per equity share (for continuing operation):						
	(1) Basic	0.001	0.002	0.000	0.003	0.002	0.005

	(2) Diluted	0.001	0.002	0.000	0.003	0.002	0.005
XIX	Earnings per equity share (for discontinued operation):						
	(1) Basic	0.000	0.000	0.000	0.000	0.000	0.000
	(2) Diluted	0.000	0.000	0.000	0.000	0.000	0.000
XX	Earning Per Share (for discontinued & continuing operations)						
	a) Basic	0.001	0.002	0.000	0.003	0.002	0.005
	b) Diluted	0.001	0.002	0.000	0.003	0.002	0.005

NOTES :

1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 14th February, 2023.

2. The previous period figures have been rearranged / regrouped, wherever necessary to confirm to current period classifications.

3. The financial results are subject to the Limited Review Report issued by the statutory auditors of the company.

4. The Financial Results have been prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standard (Ind AS) prescribed under Section 133 of the Companies Act, 2013, read with relevant rules there under in terms of Regulation 33 of SEBI (Listing and Disclosure Requirements) Regulations, 2015 and SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

FOR CITURGIA BIOCHEMICALS LIMITED


KASHI NATH
WHOLE TIME DIRECTOR
DIN No. 02072952

Date : 14th February, 2023

Place : Mumbai



G.P. KESHRI & ASSOCIATES

Chartered Accountants

Head Office: A-215/5, Chawla Complex, Vikas Marg, Shakarpur, New Delhi-110092 (Delhi)
Phone: +91 011 40157199, Mobile: +91 9818433797, Fax: +91 011 40157199,
E-Mail: gopalkeshri@yahoo.com

LIMITED REVIEW REPORT

To,
Board of Directors of
M/S Citurgia Biochemicals Limited

We have reviewed the accompanying statement of Unaudited Financial Results of M/S Citurgia Biochemicals Limited (the "Company"), for the quarter and period ended 31st December 2022, being submitted by the company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This Statement is the responsibility of the Companies Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the standard on Review Engagement (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditors of the Entity, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is Limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus accordingly, we do not express and\ audit opinion.

Based on our review conducted as above, nothing has come to our attention that caused us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards i.e. Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued hereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation and disclosed Requirements) Regulations, 2015 and SEBI circular dated 5th July 2016 including the manner in which it is to be disclosed, or that its contains any material misstatement.

For M/s G.P.Keshri & Associates
Chartered Accountants



CA. Gopal Prasad Keshri
Partner
FRN: 017251N
M.NO: 098476
UDIN:23098476BGXJVN6954
Place: New Delhi
Date: 14.02.2023

Branch Offices:

Ghaziabad(U.P.)

Dhanbad(Jharkhand)